Soligenix, Inc., a biopharmaceutical company specializing in rare diseases, has announced progress in its confirmatory Phase 3 HyBryte™ clinical trial for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The trial, known as FLASH2, is actively enrolling 80 patients and is on track to deliver top-line results in the second half of 2026. This study is a continuation of a previous Phase 3 trial, with adjustments to the primary endpoint assessment period. Further updates on enrollment progress are expected later this year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。